(917) 310-3371
Wegovy or semaglutide
The current Wegovy label says to discontinue at least two months before a planned pregnancy because semaglutide has a long half-life.
PMOS, PCOS, and GLP-1 pregnancy planning
Plan contraception, preconception timing, and treatment transitions before starting weight-management medication.
PMOS can involve irregular ovulation, but pregnancy may still occur. Weight or cycle changes during treatment can make timing less predictable. GLP-1-based obesity medicines are not fertility treatments and should not be used during pregnancy.
A reproductive plan is part of safety
Before treatment, discuss whether pregnancy is possible, the contraception method, how soon pregnancy is desired, what to do after a positive test, and which clinician will coordinate the transition.
Important distinction: The international PCOS guideline calls for effective contraception when pregnancy is possible during GLP-1 receptor agonist treatment because pregnancy safety data are lacking. Current weight-management labels direct discontinuation when pregnancy is recognized. GLP-1-based obesity medicines are not FDA approved to treat PMOS or PCOS itself.
The key decisions before treatment
A clear plan reduces the chance that a prescription conflicts with pregnancy goals or that a contraceptive interaction is missed.
Is pregnancy possible now?
Review sexual activity, contraception, menstrual unpredictability, recent pregnancy tests when clinically appropriate, and any possibility of an existing pregnancy.
How soon is pregnancy desired?
A near-term pregnancy goal may make a different treatment or timing plan more appropriate than starting long-term obesity medication.
What medicine is being considered?
Semaglutide, tirzepatide, and liraglutide have product-specific labels. Do not apply one product's instructions to another.
Could cycles change?
Weight and metabolic changes can affect menstrual patterns and pregnancy probability, but no result is guaranteed and medication is not fertility treatment.
Who manages fertility care?
Infertility evaluation, ovulation induction, and pregnancy care require the appropriate women's-health or reproductive specialist.
What happens after a positive test?
Contact the prescribing and pregnancy-care teams promptly and follow the current product label and clinician instructions.
Product-specific reproductive guidance
The label, contraception method, dose changes, and planned conception timeline all matter.
Zepbound or tirzepatide
The current Zepbound label says oral hormonal contraceptive effectiveness may be reduced after starting and after each dose escalation.
Zepbound contraception backup
The label advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after initiation and for four weeks after each dose escalation.
Saxenda or liraglutide
The current label directs discontinuation when pregnancy is recognized. Preconception timing should be set with the prescriber.
Metformin
Metformin has a different role and pregnancy evidence base. Do not assume its plan is the same as a GLP-1-based obesity medicine.
Fertility treatment
GLP-1-based obesity medication does not replace ovulation-induction or infertility care. Current PCOS guidance uses separate fertility pathways.
Safety and care boundaries
- Do not use GLP-1-based obesity medication during pregnancy for weight reduction.
- Do not wait for a missed period to discuss contraception when cycles are irregular and pregnancy is possible.
- Do not stop long-term medication or substitute another product without contacting the prescribing clinician, unless emergency instructions require immediate action.
- A positive pregnancy test, suspected pregnancy, severe vomiting, dehydration, or significant abdominal pain needs prompt clinical review.
- Weight loss before pregnancy does not guarantee ovulation, conception, a healthy pregnancy, or resolution of PMOS-related risks.
What happens during evaluation and follow-up
1. Set the timeline
State whether pregnancy is being avoided, considered later, or desired soon so medication timing is not planned in isolation.
2. Review contraception
Match the contraception method to the medicine, including the current tirzepatide warning for oral hormonal contraceptives.
3. Make a transition plan
Document when to stop, who to call after a positive test, and how weight and metabolic care will continue without unsafe exposure.
4. Coordinate follow-up
Connect primary care, women's health, obstetric, endocrinology, or fertility services according to the patient's goals and clinical complexity.
Start in NYC or Long Island
Book the existing medical weight-loss evaluation. The care team will confirm whether the first visit is virtual or in person and whether women's-health or specialist coordination is also needed.
Bronx
174th Street
932 E 174th St, Bronx, NY 10460
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Queens
Astoria
37-15 23rd Ave, Astoria, NY 11105
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Bronx
Bartow Mall
2063A Bartow Ave, Bronx, NY 10475
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Brooklyn
Crown Heights
341 Eastern Pkwy, Brooklyn, NY 11216
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Long Island
Hicksville
232 W Old Country Rd, Hicksville, NY 11801
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Queens
Jackson Heights
80-10 Northern Blvd, Jackson Heights, NY 11372
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Queens
Jamaica
90-18 Sutphin Blvd, Jamaica, NY 11435
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Queens
Long Island City
30-07 36th Ave, Astoria, NY 11106
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Long Island
Mineola
135 Mineola Blvd, Mineola, NY 11501
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Manhattan
StuyTown
259 1st Ave, New York, NY 10003
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Brooklyn
Williamsburg
308 Graham Ave, Brooklyn, NY 11211
Start a weight-management visit with an explicit contraception and pregnancy-timing discussion. The scheduling team will confirm the right visit type and current clinic availability.
Related PMOS, PCOS, and weight-management care
PMOS and PCOS weight management
Coordinate weight, metabolic health, reproductive goals, and long-term follow-up.
GLP-1 eligibility
Review general obesity-treatment criteria, safety, and whether a labeled product fits.
Metformin compared with GLP-1
Compare different medication roles for metabolic and weight-management goals.
Insurance coverage
Prepare for benefit checks, prior authorization, and pharmacy requirements.
Medical weight loss
Review Nao Medical's broader evaluation and monitoring program.
Women's health
Coordinate menstrual, contraception, and pregnancy-planning care.
Frequently asked questions
Weight-management use should stop when pregnancy is recognized under the current labels. Contact the prescriber and pregnancy-care clinician promptly for individual instructions.
The current Wegovy label says to discontinue at least two months before a planned pregnancy because semaglutide has a long half-life.
The current Zepbound label says delayed stomach emptying may reduce oral hormonal contraceptive effectiveness. It advises non-oral contraception or an added barrier method for four weeks after starting and for four weeks after each dose increase.
GLP-1-based obesity medicine is not fertility treatment. Weight and cycle changes may alter pregnancy probability, so contraception and pregnancy goals should be reviewed before treatment.
Irregular periods do not rule out pregnancy. Discuss contraception, testing when appropriate, and a plan for missed or changing cycles with the clinician.
Restarting depends on postpartum health, breastfeeding, the product label, other medicines, weight-management goals, and clinician review. Do not restart an old prescription without evaluation.
Nao Medical can support primary care, women's-health, metabolic, and weight-management evaluation. Ovulation induction or complex infertility treatment may require a reproductive specialist.
Official sources
Current guidelines and prescribing information define the evidence, approved uses, and safety boundaries. They do not determine whether a medicine is appropriate for an individual patient.
- 2023 International Evidence-based Guideline: Effective contraception recommendation when pregnancy is possible during GLP-1 receptor agonist use.
- FDA Wegovy prescribing information: Pregnancy discontinuation and two-month preconception guidance for semaglutide.
- FDA Zepbound prescribing information: Pregnancy discontinuation and oral hormonal contraceptive guidance for tirzepatide.
- FDA Saxenda prescribing information: Pregnancy guidance for liraglutide.
- Endocrine Society: PMOS name change: Current terminology and the multisystem framing of the condition.
Health information notice
General information only. The information here is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 2, 2026 from the cited sources and Nao Medical's current service information. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.